Value of SOX10 immunostaining in tumor diagnosis

Advances in Anatomic Pathology

Volumn 20, Issue 4, 2013, Pages 275-283

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Melanocytic marker; Peripheral nerve sheath tumor; Salivary gland tumor; Schwannoma; SOX10

Indexed keywords

CD146 ANTIGEN; MELAN A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOCLONAL ANTIBODY HMB 45; MONOPHENOL MONOOXYGENASE; PROTEIN S 100; TRANSCRIPTION FACTOR SOX10;

ACINAR CELL CARCINOMA; ADENOID CYSTIC CARCINOMA; ADRENAL CORTEX CARCINOMA; ANAPLASTIC CARCINOMA; ANGIOMYOLIPOMA; APPENDIX TUMOR; ARTICLE; ASTROCYTOMA; BASAL CELL CARCINOMA; BRONCHUS CARCINOID; CARCINOMA; CLEAR CELL CARCINOMA; CLEAR CELL SARCOMA; DESMOPLASTIC MELANOMA; DIFFERENTIAL DIAGNOSIS; EPENDYMOMA; EPITHELIUM TUMOR; EWING SARCOMA; FOLLICULAR CARCINOMA; GANGLIONEUROMA; GLIOBLASTOMA; GRANULAR CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LYMPH NODE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MEDULLOBLASTOMA; MELANOCYTE; MELANOMA; MERKEL CELL TUMOR; METASTATIC MELANOMA; MOLECULAR PATHOLOGY; NERVE TUMOR; NERVOUS SYSTEM TUMOR; NEURILEMOMA; NEUROBLASTOMA; NEUROFIBROMA; OLIGODENDROGLIOMA; ONCOCYTOMA; OVARY CARCINOMA; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; SALIVARY GLAND TUMOR; SCHWANN CELL; SKIN; SKIN CARCINOMA; SMALL CELL CARCINOMA; SPINDLE CELL SARCOMA; STOMACH ADENOCARCINOMA; STOMACH CARCINOID; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR DIAGNOSIS; UTERINE CERVIX CARCINOMA;

ANTIBODIES; BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SOXE TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880156900     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318297a9d0     Document Type: Article

References (78)

1. Gubbay J, Collignon J, Koopman P, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature. 1990;346:245-250.
2. Sinclair AH, Berta P, Palmer MS, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature. 1990;346:240-244.
3. Soullier S, Jay P, Poulat F, et al. Diversification pattern of the HMG and SOX family members during evolution. J Mol Evol. 1999;48:517-527. (Pubitemid 29211427)
4. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227:239-255.
5. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 1999;27:1409-1420. (Pubitemid 29206280)
6. Koopman P, Schepers G, Brenner S, et al. Origin and diversity of the SOX transcription factor gene family: genome-wide analysis in Fugu rubripes. Gene. 2004;328:177-186. (Pubitemid 38352894)
7. Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev. 1997;7:338-344. (Pubitemid 27292285)
8. Paratore C, Goerich DE, Suter U, et al. Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. Development. 2001;128:3949-3961. (Pubitemid 33040603)
9. Kelsh RN. Sorting out Sox10 functions in neural crest development. Bioessays. 2006;28:788-798. (Pubitemid 44433741)
10. Huang X, Saint-Jeannet JP. Induction of the neural crest and the opportunities of life on the edge. Dev Biol. 2004;275: 1-11. (Pubitemid 39298171)
11. Dupin E, Calloni G, Real C, et al. Neural crest progenitors and stem cells. C R Biol. 2007;330:521-529. (Pubitemid 47040690)
12. Bondurand N, GirardM, Pingault V, et al. Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot- Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet. 2001;10:2783-2795. (Pubitemid 34026460)
13. Pingault V, Bondurand N, Le Caignec C, et al. The SOX10 transcription factor: evaluation as a candidate gene for central and peripheral hereditary myelin disorders. J Neurol. 2001;248: 496-499. (Pubitemid 32661504)
14. Svaren J, Meijer D. The molecular machinery of myelin gene transcription in Schwann cells. Glia. 2008;56:1541-1551.
15. Osaka H, Hamanoue H, Yamamoto R, et al. Disrupted SOX10 regulation of GJC2 transcription causes Pelizaeus- Merzbacher-like disease. Ann Neurol. 2010;68:250-254.
16. Peirano RI, Goerich DE, Riethmacher D, et al. Protein zero gene expression is regulated by the glial transcription factor Sox10. Mol Cell Biol. 2000;20:3198-3209. (Pubitemid 30215032)
17. Stolt CC, Rehberg S, Ader M, et al. Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. Genes Dev. 2002;16:165-170. (Pubitemid 34075809)
18. Bondurand N, Pingault V, Goerich DE, et al. Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet. 2000;9:1907-1917. (Pubitemid 30642654)
19. Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 2000;14:1712-1728. (Pubitemid 30602990)
20. Lee M, Goodall J, Verastegui C, et al. Direct regulation of the Microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2. J Biol Chem. 2000;275:37978-37983. (Pubitemid 32004919)
21. Potterf SB, Mollaaghababa R, Hou L, et al. Analysis of SOX10 function in neural crest-derived melanocyte development: SOX10-dependent transcriptional control of dopachrome tautomerase. Dev Biol. 2001;237:245-257. (Pubitemid 32881118)
22. Jiao Z, Mollaaghababa R, Pavan WJ, et al. Direct interaction of Sox10 with the promoter of murine Dopachrome Tautomerase (Dct) and synergistic activation of Dct expression with Mitf. Pigment Cell Res. 2004;17:352-362. (Pubitemid 38993065)
23. Ludwig A, Rehberg S, Wegner M. Melanocyte-specific expression of dopachrome tautomerase is dependent on synergistic gene activation by the Sox10 and Mitf transcription factors. FEBS Lett. 2004;556:236-244. (Pubitemid 38058585)
24. Hou L, Arnheiter H, Pavan WJ. Interspecies difference in the regulation of melanocyte development by SOX10 and MITF. Proc Natl Acad Sci USA. 2006;103:9081-9085. (Pubitemid 43902536)
25. Murisier F, Guichard S, Beermann F. The tyrosinase enhancer is activated by Sox10 and Mitf in mouse melanocytes. Pigment Cell Res. 2007;20:173-184. (Pubitemid 46776371)
26. Murisier F, Guichard S, Beermann F. A conserved transcriptional enhancer that specifies Tyrp1 expression to melanocytes. Dev Biol. 2006;298:644-655. (Pubitemid 44441180)
27. Lang D, Chen F, Milewski R, et al. Pax3 is required for enteric ganglia formation and functions with Sox10 to modulate expression of c-ret. J Clin Invest. 2000;106:963-971.
28. Bondurand N, Kuhlbrodt K, Pingault V, et al. A molecular analysis of the Yemenite deaf-blind hypopigmentation syndrome: SOX10 dysfunction causes different neurocristopathies. Hum Mol Genet. 1999;8:1785-1789. (Pubitemid 29423890)
29. Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet. 1998;18:171-173. (Pubitemid 28082467)
30. Jacobs JM, Wilson J. An unusual demyelinating neuropathy in a patient with Waardenburg's syndrome. Acta Neuropathol. 1992;83:670-674.
31. Pingault V, Guiochon-Mantel A, Bondurand N, et al. Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-obstruction and deafness: a developmental "neural crest syndrome" related to a SOX10 mutation. Ann Neurol. 2000;48:671-676.
32. Inoue K, Shilo K, Boerkoel CF, et al. Congenital hypomyelinating neuropathy, central dysmyelination, and Waardenburg- Hirschsprung disease: phenotypes linked by SOX10 mutation. Ann Neurol. 2002;52:836-842. (Pubitemid 35403196)
33. Verheij JB, Sival DA, van der Hoeven JH, et al. Shah- Waardenburg syndrome and PCWH associated with SOX10 mutations: a case report and review of the literature. Eur J Paediatr Neurol. 2006;10:11-17.
34. Hennekam RC, Gorlin RJ. Confirmation of the Yemenite (Warburg) deaf-blind hypopigmentation syndrome. Am J Med Genet. 1996;65:146-148, 16.
35. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32:1291-1298.
36. Karamchandani JR, Nielsen TO, van de Rijn M, et al. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20:445-450.
37. Gershon TR, Oppenheimer O, Chin SS, et al. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia. 2005;7:575-584. (Pubitemid 40967758)
38. Blochin E, Nonaka D. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes. Histopathology. 2009;55:626-628.
39. Agnarsdóttir M, Sooman L, Bolander A, et al. SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res. 2010;20:468-478.
40. Ramos-Herberth FI, Karamchandani J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2010;37:944-952.
41. Jennings C, Kim J. Identification of nodal metastases in melanoma using sox-10. Am J Dermatopathol. 2011;33:474-482.
42. Yang GG, Minasyan A, Gordon J, et al. Rabbit polyclonal anti-SOX10 is a reliable IHC marker for melanoma and its mimics(abstract). Mod Pathol. 2013;26(suppl 2):124A-125A.
43. Walsh NM, Roberts JT, Orr W, et al. Desmoplastic malignant melanoma. A clinicopathologic study of 14 cases. Arch Pathol Lab Med. 1988;112:922-927.
44. Anstey A, Cerio R, Ramnarain N, et al. Desmoplastic malignant melanoma. An immunocytochemical study of 25 cases. Am J Dermatopathol. 1994;16:14-22. (Pubitemid 24062747)
45. Carlson JA, Dickersin GR, Sober AJ, et al. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995;75:478-494.
46. Shah IA, Gani OS, Wheler L. Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi. Pathol Res Pract. 1997;193:497-502. (Pubitemid 27434460)
47. Orchard GE. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J. 2000; 32:475-481.
48. Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25:197-204. (Pubitemid 32167501)
49. Granter SR, Weilbaecher KN, Quigley C, et al. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am J Dermatopathol. 2001;23:185-189. (Pubitemid 32525406)
50. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205-211. (Pubitemid 32167502)
51. Boyle JL, Haupt HM, Stern JB, et al. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch Pathol Lab Med. 2002;126:816-822. (Pubitemid 34761639)
52. Xu X, Chu AY, Pasha TL, et al. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol. 2002;26:82-87. (Pubitemid 34019996)
53. Sundram U, Harvell JD, Rouse RV, et al. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol. 2003;16:802-810. (Pubitemid 37011076)
54. Winnepenninckx V, De Vos R, Stas M, et al. New phenotypical and ultrastructural findings in spindle cell (desmoplastic/neurotropic) melanoma. Appl ImmunohistochemMolMorphol. 2003;11: 319-325. (Pubitemid 37522682)
55. Kay PA, Pinheiro AD, Lohse CM, et al. Desmoplastic melanoma of the head and neck: histopathologic and immunohistochemical study of 28 cases. Int J Surg Pathol. 2004;12:17-24. (Pubitemid 38176552)
56. Rochaix P, Lacroix-Triki M, Lamant L, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol. 2003;16:481-490. (Pubitemid 36618469)
57. Busam KJ, Kucukgol D, Sato E, et al. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol. 2005;29:400-406. (Pubitemid 40321977)
58. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (antityrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196-200. (Pubitemid 32205039)
59. Jungbluth AA, Iversen K, Coplan K, et al. T311 - an antityrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract. 2000;196:235-242. (Pubitemid 30210275)
60. Aung PP, Sarlomo-Rikala M, Lasota J, et al. KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics. Am J Surg Pathol. 2012;36:265-272.
61. King R, Googe PB, Weilbaecher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001;25:51-57. (Pubitemid 32001832)
62. Koch MB, Shih IM, Weiss SW, et al. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. Am J Surg Pathol. 2001;25:58-64. (Pubitemid 32001833)
63. Pagès C, Rochaix P, al Saati T, et al. KBA.62: a useful marker for primary and metastatic melanomas. Hum Pathol. 2008;39: 1136-1142.
64. Kang Y, Pekmezci M, Scheithauer B, et al. Utility of Sox-10 to distinguish MPNST from synovial sarcoma with a focus on intraneural synovial sarcoma. (abstract). Mod Pathol. 2013; 26(suppl 2):14A.
65. Ordónez NG, Mahfouz SM, Mackay B. Synovial sarcoma: an immunohistochemical and ultrastructural study. Hum Pathol. 1990;21:733-749. (Pubitemid 20216815)
66. Krane JF, Bertoni F, Fletcher CD. Myxoid synovial sarcoma: an underappreciated morphologic subset. Mod Pathol. 1999;12:456-462. (Pubitemid 29230605)
67. Smith TA, Machen SK, Fisher C, et al. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol. 1999;112:641-648. (Pubitemid 30214754)
68. Pelmus M, Guillou L, Hostein I, et al. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol. 2002;26:1434-1440. (Pubitemid 35239419)
69. Ordónez NG. Granular cell tumor: a review and update. Adv Anat Pathol. 1999;6:186-203.
70. Ordo'nez NG, Mackay B. Granular cell tumor: a review of the pathology and histogenesis. Ultrastruct Pathol. 1999;23:207-222. (Pubitemid 29409293)
71. Addo-Yobo SO, Straessle J, Anwar A, et al. Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2006;65:769-775. (Pubitemid 44200317)
72. Bannykh SI, Stolt CC, Kim J, et al. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol. 2006;76:115-127. (Pubitemid 43135844)
73. Rousseau A, Nutt CL, Betensky RA, et al. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol. 2006;65:1149-1156. (Pubitemid 44888831)
74. Ferletta M, Uhrbom L, Olofsson T, et al. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B - induced gliomagenesis. Mol Cancer Res. 2007;5:891-897. (Pubitemid 47416666)
75. Colin C, Virard I, Baeza N, et al. Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathol Appl Neurobiol. 2007;33: 431-439. (Pubitemid 47037890)
76. Ng TL, West R, Kwok S, et al. Positive SOX10 expression in a broad range of salivary gland tumors (abstract). Mod Pathol. 2013;26(suppl 2):310A.
77. Bakos RM, Maier T, Besch R, et al. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol. 2010;19:e89-e94.
78. Miller DD, Emley A, Yang S, et al. Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. Mod Pathol. 2012;25:505-515.